This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Poulsen, M. Articles by Tripcony, L. Search for Related Content PubMed PubMed Citation Articles by Poulsen, M. Articles by Tripcony, L. Social Bookmarking                            What's this?

High-Risk Merkel Cell Carcinoma of the Skin Treated With Synchronous Carboplatin/Etoposide and Radiation: A Trans-Tasman Radiation Oncology Group Study—TROG 96:07

From the Division of Oncology, Queensland Radium Institute; Royal Brisbane Hospital; Princess Alexandra Hospital; Department of Medical Oncology, Mater Medical Centre, Brisbane; the Department of Medical Oncology and the Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne; Department of Radiation Oncology, Newcastle Mater Misericordia Hospital, Newcastle, Australia.

Address reprint requests to Michael Poulsen, MD, Mater Queensland Radium Institute, Raymond Tee, South Brisbane, QLD 4101 Australia; e-mail: michael_poulsen{at}health.qld.gov.au.

Purpose: The effectiveness of synchronous carboplatin, etoposide, and radiation therapy was prospectively assessed in a group of patients with high-risk Merkel cell carcinoma (MCC) of the skin.

Patients and Methods: Patients were eligible if they had disease localized to the primary site and nodes, and were required to have at least one of the following high risk features: recurrence after initial therapy, involved nodes, primary tumor size greater than 1 cm, gross residual disease after surgery, or occult primary with nodes. Radiation was delivered to the primary site and nodes to a dose of 50 Gy in 25 fractions over 5 weeks and synchronous carboplatin (area under the curve, 4.5) and intravenous etoposide 80 mg/m² days 1 to 3 was given in weeks 1, 4, 7, and 10. The median age of the group was 67 (range, 43–86) years, and there were 39 males and 14 females. Involved nodes (stage II) were present in 33 cases (62%). The sites involved were head and neck (22 patients), occult primary (13 patients), upper limb (eight patients), lower limb (eight patients), and trunk (two patients).

Results: Fifty-three patients were entered between 1996 and 2001. The median potential follow-up was 48 months. There were no treatment related deaths. The 3-year overall survival, locoregional control, and distant control were 76%, 75%, and 76%, respectively. Tumor site and the presence of nodes were factors that were predictive for local control and survival. Multivariate analysis indicated that the major factor influencing survival was the presence of nodes; however, this was not a significant factor in locoregional control.

Conclusion: High levels of locoregional control and survival have been achieved with the addition of chemotherapy to radiation treatment for high-risk MCC of the skin. The role of chemoradiotherapy for high-risk MCC warrants further investigation.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. H. Ruan and M. Reeves A Merkel Cell Carcinoma Treatment Algorithm Arch Surg, June 1, 2009; 144(6): 582 - 585. [Abstract] [Full Text] [PDF]

				R. E. Warner, M. J. Quinn, G. Hruby, R. A. Scolyer, R. F. Uren, and J. F. Thompson Management of Merkel Cell Carcinoma: The Roles of Lymphoscintigraphy, Sentinel Lymph Node Biopsy and Adjuvant Radiotherapy Ann. Surg. Oncol., September 1, 2008; 15(9): 2509 - 2518. [Abstract] [Full Text] [PDF]

				P. M. Busse, J. R. Clark, V. V. Muse, and V. Liu Case 19-2008 -- A 63-Year-Old HIV-Positive Man with Cutaneous Merkel-Cell Carcinoma N. Engl. J. Med., June 19, 2008; 358(25): 2717 - 2723. [Full Text] [PDF]

				J. Jabbour, R. Cumming, R. A. Scolyer, G. Hruby, J. F. Thompson, and S. Lee Merkel Cell Carcinoma: Assessing the Effect of Wide Local Excision, Lymph Node Dissection, and Radiotherapy on Recurrence and Survival in Early-Stage Disease--Results From a Review of 82 Consecutive Cases Diagnosed Between 1992 and 2004 Ann. Surg. Oncol., June 1, 2007; 14(6): 1943 - 1952. [Abstract] [Full Text] [PDF]

				S Altintas, N Blockx, M. Huizing, J Van den Brande, L Hoekx, J. Bogers, E Van Marck, and J. Vermorken Small-cell carcinoma of the penile urethra: a case report and a short review of the literature Ann. Onc., April 1, 2007; 18(4): 801 - 804. [Full Text] [PDF]

				D Pectasides, M Pectasides, and T Economopoulos Merkel cell cancer of the skin Ann. Onc., October 1, 2006; 17(10): 1489 - 1495. [Abstract] [Full Text] [PDF]

				M. J. Veness Merkel Cell Carcinoma: Improved Outcome With the Addition of Adjuvant Therapy J. Clin. Oncol., October 1, 2005; 23(28): 7235 - 7236. [Full Text] [PDF]

				P. J. Allen, W. B. Bowne, D. P. Jaques, M. F. Brennan, K. Busam, and D. G. Coit Merkel Cell Carcinoma: Prognosis and Treatment of Patients From a Single Institution J. Clin. Oncol., April 1, 2005; 23(10): 2300 - 2309. [Abstract] [Full Text] [PDF]